<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01637623</url>
  </required_header>
  <id_info>
    <org_study_id>2012-0026</org_study_id>
    <secondary_id>U01HL105365</secondary_id>
    <secondary_id>A561000</secondary_id>
    <secondary_id>PHARM/PHARMACY/PHARMACY</secondary_id>
    <nct_id>NCT01637623</nct_id>
  </id_info>
  <brief_title>Study of Cardiovascular Disease and Obstructive Sleep Apnea</brief_title>
  <acronym>CVD/OSA</acronym>
  <official_title>Pharmacologic Interventions for Cardiovascular Disease in Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if two medicines (allopurinol and losartan) can&#xD;
      influence heart and blood vessel health compared to placebo in patients with sleep apnea who&#xD;
      are using continuous positive airway pressure (CPAP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific aims of this research project are: 1) Determine if treatment with losartan, an&#xD;
      angiotensin type I receptor (AT1R) antagonist, or allopurinol, a XO inhibitor, normalize&#xD;
      chemoreflex control of sympathetic outflow and ventilation and improve local vascular&#xD;
      regulation and stiffness; and 2) Determine if these interventions reduce the severity of&#xD;
      sleep disordered breathing and lower diurnal blood pressure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Muscle Sympathetic Nerve Activity Responses During Hypoxia</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <description>The primary outcome variable is the change in the individual slope of the MSNA - SaO2 response curve at 6 weeks and baseline between treatment groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Aortic Pulse Wave Velocity</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <description>measurement of vascular stiffness assessed before and after study drug treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular Conductance</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <description>Assessment measures of cerebral blood flow during basal conditions and during graded hypoxia before and after study drug treatment. Cerebrovascular conductance (CVC) was calculated as velocity-time integral/mean arterial pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forearm Vascular Conductance</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <description>Assessment measurements of forearm vascular conductance during basal conditions and during graded hypoxia before and after study drug treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Minute Ventilation at Normoxia</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <description>assessed before and after study drug treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Minute Ventilation During Hypoxia</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <description>assessed before and after study drug treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic Augmentation Index</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <description>assessed before and after study drug treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in PERCENT Vasodilation</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <description>Flow-mediated vasodilation (FMD) (measurement of vascular endothelial function) assessed before and after study drug treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apnea-Hypopnea Index</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <description>Severity of sleep apnea assessed before and after study drug treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PERCENT Time Spent Below 88 PERCENT Oxygen Saturation</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <description>assessed before and after study drug treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean 24-Hour Blood Pressure (Mean Arterial Pressure)</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <description>Change in mean 24 hour blood pressure (mean arterial pressure)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Severe Obstructive Sleep Apnea (Apnea Hypopnea Index &gt; 30 Events/Hour)</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic and blood pressure within range.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allopurinol 300 mg daily for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule daily for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.</description>
    <arm_group_label>Losartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Allopurinol 300 mg daily for 6 weeks</description>
    <arm_group_label>Allopurinol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule daily for 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females between ages of 21 and 65 years&#xD;
&#xD;
          -  Apnea hypopnea index or respiratory disturbance index greater than or equal to 25&#xD;
             events per hour&#xD;
&#xD;
          -  Subjects eligible for CPAP or BiPAP therapy&#xD;
&#xD;
          -  Hypertension by clinical history/diagnosis (may be controlled with non- exclusionary&#xD;
             medications) or average blood pressure &gt; 140/90 mm Hg (using last two measurements in&#xD;
             prior 12 months - or 1 prior blood pressure and 1 blood pressure at screening)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  If subject not using CPAP, having AHI &gt; 60 events/hour or oxygen saturation â‰¤ 65%&#xD;
             during sleep&#xD;
&#xD;
          -  Presence of clinical CV disease (coronary artery disease, angina, arrhythmias&#xD;
             (subjects with sinus arrhythmias will be reviewed by PI for enrollment), stroke, TIA,&#xD;
             cor pulmonale, etc.), heart failure, bruits, or diabetes mellitus by clinical&#xD;
             diagnosis/history&#xD;
&#xD;
          -  Presence of pulmonary disease that results in significant hypoxemia (resting SaO2 &lt;&#xD;
             88%)&#xD;
&#xD;
          -  Hypertriglyceridemia (triglycerides &gt;300 mg/dL), diabetes or impaired glucose&#xD;
             tolerance (fasting plasma glucose &gt; 125 mg/dL)&#xD;
&#xD;
          -  Patients taking angiotensin converting enzyme inhibitors, angiotensin receptor&#xD;
             antagonists, potassium-sparing diuretics (without accompanying loop/thiazide&#xD;
             diuretic), allopurinol, oxypurinol, febuxostat, amoxicillin, ampicillin, azathioprine&#xD;
             or mercaptopurine.&#xD;
&#xD;
          -  Patients with chronic kidney disease (Serum creatinine &gt;1.5 mg/dL) or history of&#xD;
             significant hyperkalemia (Serum potassium &gt; 5.2 mEq/L) with ARB therapy&#xD;
&#xD;
          -  Patients with history of angioedema&#xD;
&#xD;
          -  Patients with bilateral,modified radical or radical mastectomies&#xD;
&#xD;
          -  Patients who have a Serum potassium &gt; 5.0 mEq/L at the screening visit&#xD;
&#xD;
          -  Female patients who are pregnant (determined by urine pregnancy test) or breastfeeding&#xD;
&#xD;
          -  Patients with active MRSA or VRE (vancomycin resistant enterococcus) infection&#xD;
&#xD;
          -  History of adverse reaction to allopurinol,losartan, or zolpidem**&#xD;
&#xD;
          -  Patients who cannot swallow oral capsules&#xD;
&#xD;
          -  Patients who are hospitalized or who have been recently hospitalized (last 2 weeks)&#xD;
&#xD;
          -  Inability to comply with or complete the protocol or other reasons at the discretion&#xD;
             of the investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Dopp, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UW Madison School of Pharmacy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara J Morgan, PhD, PT</last_name>
    <role>Principal Investigator</role>
    <affiliation>UW Madison School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aurora Bay Care</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gundersen Lutheran</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Morgan BJ, Teodorescu M, Pegelow DF, Jackson ER, Schneider DL, Plante DT, Gapinski JP, Hetzel SJ, Dopp JM. Effects of losartan and allopurinol on cardiorespiratory regulation in obstructive sleep apnoea. Exp Physiol. 2018 Jul;103(7):941-955. doi: 10.1113/EP087006. Epub 2018 Jun 8.</citation>
    <PMID>29750475</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 29, 2012</study_first_submitted>
  <study_first_submitted_qc>July 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2012</study_first_posted>
  <results_first_submitted>August 6, 2018</results_first_submitted>
  <results_first_submitted_qc>August 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 14, 2020</results_first_posted>
  <last_update_submitted>August 13, 2020</last_update_submitted>
  <last_update_submitted_qc>August 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>High Blood Pressure</keyword>
  <keyword>Sleep Apnea</keyword>
  <keyword>Obstructive Sleep Apnea</keyword>
  <keyword>OSA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 25, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT01637623/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Losartan</title>
          <description>Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic and blood pressure within range.&#xD;
Losartan: Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.</description>
        </group>
        <group group_id="P2">
          <title>Allopurinol</title>
          <description>Allopurinol 300 mg daily for 6 weeks&#xD;
Allopurinol: Allopurinol 300 mg daily for 6 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo capsule daily for 6 weeks&#xD;
Placebo: Placebo capsule daily for 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Intervention</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Did Not Receive Intervention</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Analyzed</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>baseline analysis population includes data for those participants that were analyzed, per the participant flow</population>
      <group_list>
        <group group_id="B1">
          <title>Losartan</title>
          <description>Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic and blood pressure within range.&#xD;
Losartan: Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.</description>
        </group>
        <group group_id="B2">
          <title>Allopurinol</title>
          <description>Allopurinol 300 mg daily for 6 weeks&#xD;
Allopurinol: Allopurinol 300 mg daily for 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo capsule daily for 6 weeks&#xD;
Placebo: Placebo capsule daily for 6 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="28"/>
            <count group_id="B4" value="86"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="12"/>
                    <measurement group_id="B2" value="49" spread="8"/>
                    <measurement group_id="B3" value="47" spread="9"/>
                    <measurement group_id="B4" value="49" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Muscle Sympathetic Nerve Activity Responses During Hypoxia</title>
        <description>The primary outcome variable is the change in the individual slope of the MSNA - SaO2 response curve at 6 weeks and baseline between treatment groups.</description>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>Data is for fewer subjects than were randomized to treatment because a useable nerve signal was not obtained on all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic and blood pressure within range.&#xD;
Losartan: Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 300 mg daily for 6 weeks&#xD;
Allopurinol: Allopurinol 300 mg daily for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsule daily for 6 weeks&#xD;
Placebo: Placebo capsule daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Muscle Sympathetic Nerve Activity Responses During Hypoxia</title>
          <description>The primary outcome variable is the change in the individual slope of the MSNA - SaO2 response curve at 6 weeks and baseline between treatment groups.</description>
          <population>Data is for fewer subjects than were randomized to treatment because a useable nerve signal was not obtained on all participants.</population>
          <units>bursts/minute*%SaO2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.29"/>
                    <measurement group_id="O2" value="-0.84" spread="0.47"/>
                    <measurement group_id="O3" value="-0.71" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Following 6 weeks of therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread=".50"/>
                    <measurement group_id="O2" value="-0.66" spread="0.38"/>
                    <measurement group_id="O3" value="-0.61" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Aortic Pulse Wave Velocity</title>
        <description>measurement of vascular stiffness assessed before and after study drug treatment</description>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>Since this was a secondary outcome measure, not all participants were able to undergo this procedure since scheduling did not always allow with scheduling for primary outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic and blood pressure within range.&#xD;
Losartan: Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 300 mg daily for 6 weeks&#xD;
Allopurinol: Allopurinol 300 mg daily for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsule daily for 6 weeks&#xD;
Placebo: Placebo capsule daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Aortic Pulse Wave Velocity</title>
          <description>measurement of vascular stiffness assessed before and after study drug treatment</description>
          <population>Since this was a secondary outcome measure, not all participants were able to undergo this procedure since scheduling did not always allow with scheduling for primary outcome measure.</population>
          <units>m/s</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" lower_limit="-1.0" upper_limit="-0.2"/>
                    <measurement group_id="O2" value="-0.03" lower_limit="-0.5" upper_limit="0.4"/>
                    <measurement group_id="O3" value="0.2" lower_limit="-0.3" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebrovascular Conductance</title>
        <description>Assessment measures of cerebral blood flow during basal conditions and during graded hypoxia before and after study drug treatment. Cerebrovascular conductance (CVC) was calculated as velocity-time integral/mean arterial pressure.</description>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>Since this was a secondary outcome measure, not all participants were able to undergo this procedure since scheduling did not always allow with scheduling for primary outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic and blood pressure within range.&#xD;
Losartan: Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 300 mg daily for 6 weeks&#xD;
Allopurinol: Allopurinol 300 mg daily for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsule daily for 6 weeks&#xD;
Placebo: Placebo capsule daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebrovascular Conductance</title>
          <description>Assessment measures of cerebral blood flow during basal conditions and during graded hypoxia before and after study drug treatment. Cerebrovascular conductance (CVC) was calculated as velocity-time integral/mean arterial pressure.</description>
          <population>Since this was a secondary outcome measure, not all participants were able to undergo this procedure since scheduling did not always allow with scheduling for primary outcome measure.</population>
          <units>cm/sec/mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.13"/>
                    <measurement group_id="O2" value="0.27" spread="0.97"/>
                    <measurement group_id="O3" value="0.33" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After six weeks treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.14"/>
                    <measurement group_id="O2" value="0.31" spread="0.12"/>
                    <measurement group_id="O3" value="0.34" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forearm Vascular Conductance</title>
        <description>Assessment measurements of forearm vascular conductance during basal conditions and during graded hypoxia before and after study drug treatment.</description>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>Participants were not able to conduct all procedures due to scheduling and on occasion, difficulty obtaining a signal. Prioritization of primary outcome measure was the goal.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic and blood pressure within range.&#xD;
Losartan: Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 300 mg daily for 6 weeks&#xD;
Allopurinol: Allopurinol 300 mg daily for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsule daily for 6 weeks&#xD;
Placebo: Placebo capsule daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Forearm Vascular Conductance</title>
          <description>Assessment measurements of forearm vascular conductance during basal conditions and during graded hypoxia before and after study drug treatment.</description>
          <population>Participants were not able to conduct all procedures due to scheduling and on occasion, difficulty obtaining a signal. Prioritization of primary outcome measure was the goal.</population>
          <units>ml/min^-1 dL^-1 mmHg^-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.21"/>
                    <measurement group_id="O2" value="0.43" spread="0.2"/>
                    <measurement group_id="O3" value="0.49" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 6 weeks of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.17"/>
                    <measurement group_id="O2" value="0.55" spread="0.31"/>
                    <measurement group_id="O3" value="0.51" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Minute Ventilation at Normoxia</title>
        <description>assessed before and after study drug treatment</description>
        <time_frame>baseline and 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic and blood pressure within range.&#xD;
Losartan: Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 300 mg daily for 6 weeks&#xD;
Allopurinol: Allopurinol 300 mg daily for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsule daily for 6 weeks&#xD;
Placebo: Placebo capsule daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Minute Ventilation at Normoxia</title>
          <description>assessed before and after study drug treatment</description>
          <units>normoxia - L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline - normoxia in L/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="1.7"/>
                    <measurement group_id="O2" value="9.3" spread="2.1"/>
                    <measurement group_id="O3" value="9.3" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>six weeks - normoxia in L/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="2.1"/>
                    <measurement group_id="O2" value="9.8" spread="2.6"/>
                    <measurement group_id="O3" value="8.8" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Minute Ventilation During Hypoxia</title>
        <description>assessed before and after study drug treatment</description>
        <time_frame>baseline and 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic and blood pressure within range.&#xD;
Losartan: Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 300 mg daily for 6 weeks&#xD;
Allopurinol: Allopurinol 300 mg daily for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsule daily for 6 weeks&#xD;
Placebo: Placebo capsule daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Minute Ventilation During Hypoxia</title>
          <description>assessed before and after study drug treatment</description>
          <units>hypoxia - L/min*%SaO2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hypoxia - baseline in L/min*PERCENTSaO2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.28"/>
                    <measurement group_id="O2" value="-0.53" spread="0.41"/>
                    <measurement group_id="O3" value="-0.44" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hypoxia - after six weeks treatment in L/min*%SaO2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.25"/>
                    <measurement group_id="O2" value="-0.43" spread="0.37"/>
                    <measurement group_id="O3" value="-0.48" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aortic Augmentation Index</title>
        <description>assessed before and after study drug treatment</description>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>The number of participants differ between outcome measures due to difficulty in obtaining a viable signal for one outcome vs another and based on scheduling to prioritize the primary outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic and blood pressure within range.&#xD;
Losartan: Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 300 mg daily for 6 weeks&#xD;
Allopurinol: Allopurinol 300 mg daily for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsule daily for 6 weeks&#xD;
Placebo: Placebo capsule daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Aortic Augmentation Index</title>
          <description>assessed before and after study drug treatment</description>
          <population>The number of participants differ between outcome measures due to difficulty in obtaining a viable signal for one outcome vs another and based on scheduling to prioritize the primary outcome measure.</population>
          <units>PERCENT of the pulse pressure</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="12.7" upper_limit="22.0"/>
                    <measurement group_id="O2" value="18.8" lower_limit="14.5" upper_limit="23.1"/>
                    <measurement group_id="O3" value="21.5" lower_limit="16.8" upper_limit="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>following six weeks of therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" lower_limit="11.4" upper_limit="20.7"/>
                    <measurement group_id="O2" value="16.7" lower_limit="12.5" upper_limit="21.0"/>
                    <measurement group_id="O3" value="22.5" lower_limit="17.7" upper_limit="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in PERCENT Vasodilation</title>
        <description>Flow-mediated vasodilation (FMD) (measurement of vascular endothelial function) assessed before and after study drug treatment</description>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>The number of participants differ between primary and secondary outcome variables due to occasional inability to obtain a viable signal for the variable and due to scheduling difficulties and prioritizing the primary outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic and blood pressure within range.&#xD;
Losartan: Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 300 mg daily for 6 weeks&#xD;
Allopurinol: Allopurinol 300 mg daily for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsule daily for 6 weeks&#xD;
Placebo: Placebo capsule daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in PERCENT Vasodilation</title>
          <description>Flow-mediated vasodilation (FMD) (measurement of vascular endothelial function) assessed before and after study drug treatment</description>
          <population>The number of participants differ between primary and secondary outcome variables due to occasional inability to obtain a viable signal for the variable and due to scheduling difficulties and prioritizing the primary outcome measure.</population>
          <units>% change in Max relative FMD</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" lower_limit="0.19" upper_limit="2.57"/>
                    <measurement group_id="O2" value="0.18" lower_limit="-0.97" upper_limit="1.32"/>
                    <measurement group_id="O3" value="-1.06" lower_limit="-2.28" upper_limit="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apnea-Hypopnea Index</title>
        <description>Severity of sleep apnea assessed before and after study drug treatment</description>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>The number of participants differ between primary and secondary outcome variables due to occasional inability to obtain a viable signal for the variable and due to scheduling difficulties and prioritizing the primary outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic and blood pressure within range.&#xD;
Losartan: Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 300 mg daily for 6 weeks&#xD;
Allopurinol: Allopurinol 300 mg daily for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsule daily for 6 weeks&#xD;
Placebo: Placebo capsule daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Apnea-Hypopnea Index</title>
          <description>Severity of sleep apnea assessed before and after study drug treatment</description>
          <population>The number of participants differ between primary and secondary outcome variables due to occasional inability to obtain a viable signal for the variable and due to scheduling difficulties and prioritizing the primary outcome measure.</population>
          <units>events/hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="27" upper_limit="58"/>
                    <measurement group_id="O2" value="33" lower_limit="24" upper_limit="50"/>
                    <measurement group_id="O3" value="35" lower_limit="18" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>after six weeks of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="25" upper_limit="67"/>
                    <measurement group_id="O2" value="45" lower_limit="22" upper_limit="68"/>
                    <measurement group_id="O3" value="26" lower_limit="15" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PERCENT Time Spent Below 88 PERCENT Oxygen Saturation</title>
        <description>assessed before and after study drug treatment</description>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>The number of participants differ between primary and secondary outcome variables due to occasional inability to obtain a viable signal for the variable and due to scheduling difficulties and prioritizing the primary outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic and blood pressure within range.&#xD;
Losartan: Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 300 mg daily for 6 weeks&#xD;
Allopurinol: Allopurinol 300 mg daily for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsule daily for 6 weeks&#xD;
Placebo: Placebo capsule daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>PERCENT Time Spent Below 88 PERCENT Oxygen Saturation</title>
          <description>assessed before and after study drug treatment</description>
          <population>The number of participants differ between primary and secondary outcome variables due to occasional inability to obtain a viable signal for the variable and due to scheduling difficulties and prioritizing the primary outcome measure.</population>
          <units>percentage of total sleep time</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="4" upper_limit="25"/>
                    <measurement group_id="O2" value="5" lower_limit="1" upper_limit="15"/>
                    <measurement group_id="O3" value="5" lower_limit="1" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>following six weeks of therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="2" upper_limit="35"/>
                    <measurement group_id="O2" value="8" lower_limit="2" upper_limit="18"/>
                    <measurement group_id="O3" value="3" lower_limit="1" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean 24-Hour Blood Pressure (Mean Arterial Pressure)</title>
        <description>Change in mean 24 hour blood pressure (mean arterial pressure)</description>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>The number of participants differ between primary and secondary outcome variables due to occasional inability to obtain a viable signal for the variable and due to scheduling difficulties and prioritizing the primary outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic and blood pressure within range.&#xD;
Losartan: Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 300 mg daily for 6 weeks&#xD;
Allopurinol: Allopurinol 300 mg daily for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsule daily for 6 weeks&#xD;
Placebo: Placebo capsule daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean 24-Hour Blood Pressure (Mean Arterial Pressure)</title>
          <description>Change in mean 24 hour blood pressure (mean arterial pressure)</description>
          <population>The number of participants differ between primary and secondary outcome variables due to occasional inability to obtain a viable signal for the variable and due to scheduling difficulties and prioritizing the primary outcome measure.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.73" lower_limit="-7.67" upper_limit="-1.79"/>
                    <measurement group_id="O2" value="-2.58" lower_limit="-5.51" upper_limit="0.34"/>
                    <measurement group_id="O3" value="1.02" lower_limit="-2.20" upper_limit="4.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 6 weeks</time_frame>
      <desc>Adverse Events Data reported for all participants who started the study, per participant flow.</desc>
      <group_list>
        <group group_id="E1">
          <title>Losartan</title>
          <description>Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic and blood pressure within range.&#xD;
Losartan: Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.</description>
        </group>
        <group group_id="E2">
          <title>Allopurinol</title>
          <description>Allopurinol 300 mg daily for 6 weeks&#xD;
Allopurinol: Allopurinol 300 mg daily for 6 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo capsule daily for 6 weeks&#xD;
Placebo: Placebo capsule daily for 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John M. Dopp</name_or_title>
      <organization>University of Wisconsin School of Pharmacy</organization>
      <phone>608-265-9352</phone>
      <email>john.dopp@wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

